Non-fucosylated Anti-Human CD20 (Ibritumomab) Therapeutic Antibody (CAT#: BioBet-029ZP) Datasheet

MS4A1

membrane spanning 4-domains A1

This gene encodes a member of the membrane-spanning 4A gene family. Members of this nascent protein family are characterized by common structural features and similar intron/exon splice boundaries and display unique expression patterns among hematopoietic cells and nonlymphoid tissues. This gene encodes a B-lymphocyte surface molecule which plays a role in the development and differentiation of B-cells into plasma cells. This family member is localized to 11q12, among a cluster of family members. Alternative splicing of this gene results in two transcript variants which encode the same protein.

B1, S7, Bp35, CD20, CVID5, MS4A2, LEU-16

Plasma membrane

Diseases associated with MS4A1 include Immunodeficiency, Common Variable, 5 and Common Variable Immunodeficiency.

Its related pathways are Hematopoietic cell lineage and Hematopoietic Stem Cells and Lineage-specific Markers.

b lymphocyte-specific membrane protein, which is involved in the regulation of cellular calcium influx necessary for the development, differentiation and activation of b lymphocytes (PubMed:3925015, PubMed:7684739, PubMed:12920111). After activation of b-cell receptor/BCR, it acts as a component of stored and operated calcium (SOC) channels to promote calcium influx (PubMed:7684739, PubMed:12920111, PubMed:18474602).

Cancer antibody; Developmental Biology antibody; Immune System antibody; B cell Marker antibody; Immature B Cell Marker antibody; Inflammatory Cell Marker antibody; Tumor-infiltrating Lymphocyte Study antibody

Phosphorylated. Might be functionally regulated by protein kinase(s).

Protein Based Therapies
Monoclonal antibody (mAb)

IgG1

Ibritumomab

Mouse

Human

Ibritumomab tiuxetan, trade name Zevalin. The drug combines the monoclonal mouse IgG1 antibody ibritumomab with the chelator tiuxetan to treat relapsed or refractory B-cell non-Hodgkin's lymphoma. Ibritumomab tiuxetan is a monoclonal antibody radioimmunotherapy that targets the CD20 antigen on the surface of B cells and malignant B lymphocytes.

Follicular Non-Hodgkin's Lymphoma
Follicular Non-Hodgkin's Lymphoma Refractory

Ibritumomab

Ibritumomab tiuxetan targets binding to the CD20 antigen found on the surface of normal and malignant B cells (instead of B cell precursors), thereby killing and killing B cells and some nearby cells through radiation of attached isotopes (mainly beta emission) . In addition, the antibody itself may trigger cell death through antibody-dependent cell-mediated cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and apoptosis. These actions collectively eliminate B cells in the human body, thereby enabling lymphoid stem cells to form a new healthy B cell population.

Follicular Non-Hodgkin's Lymphoma
Follicular Non-Hodgkin's Lymphoma Refractory